Blood Test Predicts Alzheimer's Risk Decade Before Symptoms Emerge

Researchers analyzed data from nearly 2,700 cognitively healthy adults with an average age of 70 to determine the prognostic value of the p-tau217 biomarker. The study, published in JAMA, found that participants with very high levels of the protein faced a 78% risk of developing cognitive impairment within a decade. Even those with only moderately elevated levels showed a significant 45% risk over the same period, providing predictive insights that extend beyond traditional brain scans and genetic testing.

Rachel F. Buckley of Harvard Medical School noted that this evidence offers a clear path to identifying patients for early intervention clinical trials. While the test is not a standalone diagnostic tool—as factors like age, genetics, and kidney function also influence dementia risk—it marks a fundamental change in how clinicians might approach long-term brain health. By detecting the disease in its silent stage, doctors hope to eventually utilize preventative treatments before memory loss occurs, potentially altering the trajectory of the condition for aging populations.